Last edition
News about "Otsuka ulefnersen"
Ionis Reports Positive Phase 3 FUSION Study Results
Ionis reports positive phase 3 FUSION results for ulefnersen, advancing a potential first disease-modifying treatment for FUS-ALS.
Otsuka Ulefnersen | 24/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members